Cargando…
Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots
BACKGROUND: Dried blood spots (DBS) are an established specimen type for clinical testing given their low cost, ease of collection and storage, and convenient shipping capabilities through the postal system. These attributes are complementary to the expansion of SARS-CoV-2 serologic testing, which m...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162624/ https://www.ncbi.nlm.nih.gov/pubmed/34048503 http://dx.doi.org/10.1371/journal.pone.0252621 |
_version_ | 1783700755961610240 |
---|---|
author | Turgeon, Coleman T. Sanders, Karen A. Rinaldo, Piero Granger, Dane Hilgart, Heather Matern, Dietrich Theel, Elitza S. |
author_facet | Turgeon, Coleman T. Sanders, Karen A. Rinaldo, Piero Granger, Dane Hilgart, Heather Matern, Dietrich Theel, Elitza S. |
author_sort | Turgeon, Coleman T. |
collection | PubMed |
description | BACKGROUND: Dried blood spots (DBS) are an established specimen type for clinical testing given their low cost, ease of collection and storage, and convenient shipping capabilities through the postal system. These attributes are complementary to the expansion of SARS-CoV-2 serologic testing, which may be used to inform community seroprevalence rates. METHODS: The Luminex xMAP SARS-CoV-2 Multi-Antigen assay utilizes magnetic beads labeled with three viral antigens (nucleocapsid [NC], receptor binding domain [RBD], spike S1 subunit) to detect anti-viral IgG-class antibodies, and has Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for use in serum and plasma. This assay was modified for use with DBS and validated against paired sera tested by one of two reference assays: the Roche Diagnostics Elecsys anti-SARS-CoV-2 ECLIA or the Euroimmun anti-SARS-CoV-2 IgG ELISA. RESULTS: 159 paired DBS and serum specimens analyzed using the modified Luminex xMAP assay on DBS and the reference methods on serum showed an overall concordance of 96.9% (154/159). Use of multivariate pattern recognition software (CLIR) for post-analytical interpretation of the Luminex xMAP DBS assay results, instead of manufacturer provided interpretive thresholds, increased overall qualitative result concordance to 99.4% (158/159) between the modified Luminex xMAP DBS and reference results. CONCLUSIONS: Use of DBS for detection of antibodies against SARS-CoV-2 provides comparable results to those obtained using serum. DBS concordance was improved with multivariate pattern recognition software (CLIR). We demonstrate that DBS are a reliable specimen type for SARS-CoV-2 antibody detection using the modified Luminex xMAP assay. |
format | Online Article Text |
id | pubmed-8162624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-81626242021-06-10 Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots Turgeon, Coleman T. Sanders, Karen A. Rinaldo, Piero Granger, Dane Hilgart, Heather Matern, Dietrich Theel, Elitza S. PLoS One Research Article BACKGROUND: Dried blood spots (DBS) are an established specimen type for clinical testing given their low cost, ease of collection and storage, and convenient shipping capabilities through the postal system. These attributes are complementary to the expansion of SARS-CoV-2 serologic testing, which may be used to inform community seroprevalence rates. METHODS: The Luminex xMAP SARS-CoV-2 Multi-Antigen assay utilizes magnetic beads labeled with three viral antigens (nucleocapsid [NC], receptor binding domain [RBD], spike S1 subunit) to detect anti-viral IgG-class antibodies, and has Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for use in serum and plasma. This assay was modified for use with DBS and validated against paired sera tested by one of two reference assays: the Roche Diagnostics Elecsys anti-SARS-CoV-2 ECLIA or the Euroimmun anti-SARS-CoV-2 IgG ELISA. RESULTS: 159 paired DBS and serum specimens analyzed using the modified Luminex xMAP assay on DBS and the reference methods on serum showed an overall concordance of 96.9% (154/159). Use of multivariate pattern recognition software (CLIR) for post-analytical interpretation of the Luminex xMAP DBS assay results, instead of manufacturer provided interpretive thresholds, increased overall qualitative result concordance to 99.4% (158/159) between the modified Luminex xMAP DBS and reference results. CONCLUSIONS: Use of DBS for detection of antibodies against SARS-CoV-2 provides comparable results to those obtained using serum. DBS concordance was improved with multivariate pattern recognition software (CLIR). We demonstrate that DBS are a reliable specimen type for SARS-CoV-2 antibody detection using the modified Luminex xMAP assay. Public Library of Science 2021-05-28 /pmc/articles/PMC8162624/ /pubmed/34048503 http://dx.doi.org/10.1371/journal.pone.0252621 Text en © 2021 Turgeon et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Turgeon, Coleman T. Sanders, Karen A. Rinaldo, Piero Granger, Dane Hilgart, Heather Matern, Dietrich Theel, Elitza S. Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots |
title | Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots |
title_full | Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots |
title_fullStr | Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots |
title_full_unstemmed | Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots |
title_short | Validation of a multiplex flow immunoassay for detection of IgG antibodies against SARS-CoV-2 in dried blood spots |
title_sort | validation of a multiplex flow immunoassay for detection of igg antibodies against sars-cov-2 in dried blood spots |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162624/ https://www.ncbi.nlm.nih.gov/pubmed/34048503 http://dx.doi.org/10.1371/journal.pone.0252621 |
work_keys_str_mv | AT turgeoncolemant validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots AT sanderskarena validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots AT rinaldopiero validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots AT grangerdane validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots AT hilgartheather validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots AT materndietrich validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots AT theelelitzas validationofamultiplexflowimmunoassayfordetectionofiggantibodiesagainstsarscov2indriedbloodspots |